Oncotarget

Research Papers:

PAX3d mRNA over 2.76 copies/μL in the bloodstream predicts cutaneous malignant melanoma relapse

Chiara Autilio, Carmela Paolillo, Maria Michela Lavieri, Krizia Pocino, Elisa De Paolis, Enrico Di Stasio, Paolo Marchetti, Cappellini Antonini Gian Carlo and Ettore Capoluongo _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:85479-85491. https://doi.org/10.18632/oncotarget.20177

Metrics: PDF 1031 views  |   HTML 1772 views  |   ?  


Abstract

Chiara Autilio1, Carmela Paolillo1, Maria Michela Lavieri2, Krizia Pocino1, Elisa De Paolis1, Enrico Di Stasio3, Paolo Marchetti4, Cappellini Antonini Gian Carlo6 and Ettore Capoluongo1,5,7

1Institute of Clinical Biochemistry, Laboratory of Clinical Molecular Diagnostics, Fondazione Policlinico “A. Gemelli”, Catholic University of the Sacred Heart, Rome, Italy

2Unit of Dermatology, “Cristo Re” Hospital, Rome, Italy

3Laboratory of Clinical Biochemistry, Fondazione Policlinico “A. Gemelli”, Rome, Italy

4Sant’Andrea Hospital, Rome, Italy

5Laboratory of Advanced Molecular Diagnostics (DIMA), Istituto Dermopatico dell’Immacolata, Fondazione Luigi Maria Monti, IRCCS, Rome, Italy

6Oncology Unit Immacolata Dermatological Institute (IDI), Rome, Italy

7“Molipharma Srl” a Spinoff of Catholic University, Campobasso, Italy

Correspondence to:

Ettore Capoluongo, email: e.capoluongo@idi.it, ettoredomenico.capoluongo@unicatt.it

Keywords: melanoma molecular biomarker, qRT-PCR, melanoma relapse, circulating tumor cells, PAX3

Received: June 17, 2017     Accepted: July 25, 2017     Published: August 11, 2017

ABSTRACT

Objective: The aim of this study was to evaluate if our molecular algorithm, based on tumor circulating transcripts, may predict relapse risk in cutaneous malignant melanoma (CMM).

Results: The multi-marker panel was able to differentiate patients with CMM from HC with high diagnostic sensitivity and specificity, especially for MITF-m and TGFB2 (91–100%) whose levels decreased during follow-up of recurrence-free patients, and remained stable in the case of relapse. PAX3d higher than 2.76 copies/μL emerged as a promising biomarker [specificity = 75–93% and negative predictive value = 75–98%] to stratify subjects at high risk of CMM recurrence independently of age, gender and AJCC staging [OD = 9.5(3.2–28.0), p < 0.001]. The survival analysis confirmed PAX3d performance in relapse prediction with significant differences in recurrence risk 12 months after the basal time-point (p = 0.008).

Materials and Methods: Peripheral blood was collected from 111 CMM patients and from 87 healthy controls (HC) randomly selected. Each specimen was examined by qRT-PCR analysis for the expression of 3 tumor-related transcripts (PAX3d, MITF-m and TGFB2) at diagnosis, and at the following 6 and 12 months during clinical monitoring.

Conclusions: We demonstrated the usefulness of our molecular algorithm to indirectly detect circulating melanoma cells in blood, along with PAX3d capability to assess patients’ progression and relapse prediction.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20177